Ieq Capital LLC Invests $934,000 in PROCEPT BioRobotics Corporation $PRCT

Ieq Capital LLC purchased a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 41,384 shares of the company’s stock, valued at approximately $934,000.

Several other hedge funds have also recently added to or reduced their stakes in PRCT. Advisory Services Network LLC lifted its holdings in PROCEPT BioRobotics by 1.3% in the 2nd quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock valued at $1,158,000 after purchasing an additional 250 shares in the last quarter. Osaic Holdings Inc. grew its holdings in shares of PROCEPT BioRobotics by 20.3% during the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock worth $115,000 after buying an additional 337 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of PROCEPT BioRobotics by 4.7% during the fourth quarter. ProShare Advisors LLC now owns 9,726 shares of the company’s stock worth $306,000 after buying an additional 438 shares in the last quarter. California State Teachers Retirement System raised its position in shares of PROCEPT BioRobotics by 1.4% in the second quarter. California State Teachers Retirement System now owns 49,446 shares of the company’s stock valued at $2,848,000 after buying an additional 693 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of PROCEPT BioRobotics by 436.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after buying an additional 746 shares during the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics Trading Down 2.2%

PRCT opened at $20.60 on Friday. The stock has a market capitalization of $1.18 billion, a PE ratio of -10.62 and a beta of 0.89. PROCEPT BioRobotics Corporation has a one year low of $16.67 and a one year high of $42.43. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55. The business’s 50 day moving average price is $20.34 and its 200 day moving average price is $23.96.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The business had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. During the same period last year, the business earned ($0.35) EPS. PROCEPT BioRobotics’s revenue was up 19.3% compared to the same quarter last year. As a group, equities research analysts expect that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on PRCT shares. Wells Fargo & Company lowered shares of PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price target on the stock. in a research report on Wednesday, August 5th. Evercore set a $23.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. UBS Group lowered shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 target price on the stock. in a research note on Tuesday, July 28th. Citigroup cut PROCEPT BioRobotics to a “hold” rating in a report on Thursday, July 2nd. Finally, William Blair lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $28.00.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Negative Sentiment: Several firms reiterated that investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek appointment as lead plaintiff. The concentration of deadline notices increases visibility around the litigation and adds a legal overhang for the stock. Rosen Law Firm deadline notice
• Negative Sentiment: The lawsuits allege that PROCEPT did not adequately disclose the use of discounts and late-quarter bulk sales to pull forward handpiece demand, potentially contributing to excess inventory at customers. The complaints also allege that investors were later informed about field-inventory optimization and weaker procedure or handpiece sales. These allegations have not been proven in court. SueWallSt investor alert
• Negative Sentiment: Hagens Berman and other firms characterized the case as following repeated handpiece-sales underperformance and disclosures of excess customer inventory. One notice cited an approximately 18% decline associated with inventory-related disclosures, while another said the shares had fallen more than 75% from their class-period high. Hagens Berman investor alert
• Neutral Sentiment: The repeated announcements primarily seek to recruit investors and establish a lead plaintiff; they do not represent new operating results or a final finding of wrongdoing. However, the litigation could create legal costs, management distraction, and uncertainty regarding PROCEPT’s sales practices and demand outlook. Howard G. Smith deadline alert

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Larry L. Wood acquired 23,900 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $20.85 per share, with a total value of $498,315.00. Following the transaction, the chief executive officer owned 23,900 shares of the company’s stock, valued at $498,315. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders sold 1,000 shares of company stock worth $28,480. Corporate insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.